These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 12111110

  • 1. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
    [Abstract] [Full Text] [Related]

  • 2. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS.
    J Clin Oncol; 2007 Mar 01; 25(7):793-8. PubMed ID: 17283364
    [Abstract] [Full Text] [Related]

  • 3. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F, Lehoczky D, Demeter J.
    Orv Hetil; 1999 Aug 01; 140(31):1731-5. PubMed ID: 10463032
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C.
    Leukemia; 2003 Feb 01; 17(2):323-7. PubMed ID: 12592330
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O'Brien S.
    Cancer; 2004 Jun 15; 100(12):2583-91. PubMed ID: 15197800
    [Abstract] [Full Text] [Related]

  • 8. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 9. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia.
    Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE.
    Cancer; 2007 Jun 01; 109(11):2291-8. PubMed ID: 17514743
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.
    Perkins JG, Flynn JM, Howard RS, Byrd JC.
    Cancer; 2002 Apr 01; 94(7):2033-9. PubMed ID: 11932906
    [Abstract] [Full Text] [Related]

  • 13. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
    Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, Piccirillo N, Chiusolo P, Sorà F, Innocenti I, Sica S, Leone G.
    Ann Hematol; 2008 Nov 01; 87(11):891-8. PubMed ID: 18587576
    [Abstract] [Full Text] [Related]

  • 14. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
    Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M, German CLL Study Group (GCLLSG).
    Br J Haematol; 2007 Jan 01; 136(1):63-72. PubMed ID: 17083342
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.
    Cancer; 2006 Sep 01; 107(5):916-24. PubMed ID: 16832816
    [Abstract] [Full Text] [Related]

  • 18. The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
    Polizzotto MN, Tam CS, Milner A, Januszewicz EH, Prince HM, Westerman D, Wolf MM, Seymour JF.
    Cancer; 2006 Aug 15; 107(4):773-80. PubMed ID: 16847886
    [Abstract] [Full Text] [Related]

  • 19. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
    Foon KA, Boyiadzis M, Land SR, Marks S, Raptis A, Pietragallo L, Meisner D, Laman A, Sulecki M, Butchko A, Schaefer P, Lenzer D, Tarhini A.
    J Clin Oncol; 2009 Feb 01; 27(4):498-503. PubMed ID: 19075274
    [Abstract] [Full Text] [Related]

  • 20. [Treatment with fludarabine of chronic refractory lymphoid leukemia].
    Herrero M, Cabrera JR, Briz M, Forés R, Díez JL, Regidor C, Sanjuán I, Fernández MN.
    Sangre (Barc); 1995 Apr 01; 40(2):115-9. PubMed ID: 7784940
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.